litlas
ログインアカウント作成

Anas Younes

1990–2024 年に発表

144
論文数
29,856
被引用数
100
h 指数
144
i10 指数

被引用数

Anas Younes の年別被引用数1984 年: 被引用 1 件1989 年: 被引用 1 件1991 年: 被引用 1 件1992 年: 被引用 2 件1993 年: 被引用 12 件1994 年: 被引用 26 件1995 年: 被引用 30 件1996 年: 被引用 33 件1997 年: 被引用 22 件1998 年: 被引用 12 件1999 年: 被引用 34 件2000 年: 被引用 46 件2001 年: 被引用 47 件2002 年: 被引用 53 件2003 年: 被引用 86 件2004 年: 被引用 81 件2005 年: 被引用 117 件2006 年: 被引用 108 件2007 年: 被引用 102 件2008 年: 被引用 140 件2009 年: 被引用 141 件2010 年: 被引用 110 件2011 年: 被引用 169 件2012 年: 被引用 234 件2013 年: 被引用 181 件2014 年: 被引用 186 件2015 年: 被引用 217 件2016 年: 被引用 184 件2017 年: 被引用 283 件2018 年: 被引用 276 件2019 年: 被引用 985 件2020 年: 被引用 1,037 件2021 年: 被引用 981 件2022 年: 被引用 737 件2023 年: 被引用 581 件2024 年: 被引用 788 件2025 年: 被引用 355 件2026 年: 被引用 8 件1985〜1988 年は被引用が無いため表示していません1990 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,157 件、この内訳の 29.8%中国: 引用元論文 864 件、この内訳の 8.1%ドイツ: 引用元論文 649 件、この内訳の 6.1%イギリス: 引用元論文 608 件、この内訳の 5.7%イタリア: 引用元論文 595 件、この内訳の 5.6%フランス: 引用元論文 516 件、この内訳の 4.9%カナダ: 引用元論文 392 件、この内訳の 3.7%スペイン: 引用元論文 338 件、この内訳の 3.2%オーストラリア: 引用元論文 305 件、この内訳の 2.9%スイス: 引用元論文 281 件、この内訳の 2.7%日本: 引用元論文 279 件、この内訳の 2.6%オランダ: 引用元論文 257 件、この内訳の 2.4%
0%29.8%その他 22.3%

機関

分野

  • Medicine64.8%
  • Biochemistry, Genetics and Molecular Biology27%
  • Immunology and Microbiology5.3%
  • Computer Science0.6%
  • Materials Science0.4%
  • Chemistry0.4%
  • その他1.5%

トピック

  • Lymphoma Diagnosis and Treatment11%
  • CAR-T cell therapy research5.4%
  • Chronic Lymphocytic Leukemia Research4%
  • Cancer Immunotherapy and Biomarkers3.3%
  • Immune Cell Function and Interaction2.9%
  • Viral-associated cancers and disorders2.7%
  • その他70.7%

共著者

全論文

検索で開く
  1. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer

    著者: Marilyn M. Li, Michael Datto, Eric J. Duncavage, Shashikant Kulkarni, Neal I. Lindeman, Somak Roy, Apostolia M. Tsimberidou, Cindy L. Vnencak‐Jones, Daynna J. Wolff, Anas Younes, Marina N. Nikiforova - Journal of Molecular Diagnostics 2016 被引用: 2,005

  2. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

    著者: Anas Younes, Laurie H. Sehn, Peter Johnson, Pier Luigi Zinzani, Xiaonan Hong, Jun Zhu, Caterina Patti, David Belada, Olga Samoilova, Cheolwon Suh, Sirpa Leppä, Shinya Rai, Mehmet Turgut, Wojciech Jurczak, Matthew C. Cheung, Ronit Gurion, Su‐Peng Yeh, Andrés López‐Hernandez, Ulrich Dührsen, Catherine Thiéblemont, Carlos Chiattone, Sriram Balasubramanian, Jodi Carey, Grace Liu, S. Martin Shreeve, Steven Sun, Sen Hong Zhuang, Jessica Vermeulen, Louis M. Staudt, Wyndham H. Wilson, on behalf of the PHOENIX investigators - Journal of Clinical Oncology 2019 被引用: 616

  3. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

    著者: David S. Hong, Razelle Kurzrock, Youngsoo Kim, Richard Woessner, Anas Younes, John Nemunaitis, Nathan Fowler, Tianyuan Zhou, Joanna Schmidt, Minji Jo, Samantha J. Lee, Mason Yamashita, Steven G. Hughes, Luis Fayad, Sarina A. Piha‐Paul, Murali V.P. Nadella, Morvarid Mohseni, Deborah Lawson, Corinne Reimer, David C. Blakey, Xiaokun Xiao, Jeff Hsu, Alexey S. Revenko, Brett P. Monia, A. Robert MacLeod - Science Translational Medicine 2015 被引用: 440

  4. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

    著者: Joseph M. Connors, Wojciech Jurczak, David J. Straus, Stephen M. Ansell, Won S. Kim, Andrea Gallamini, Anas Younes, Sergey Alekseev, Árpád Illés, Marco Picardi, Ewa Lech‐Marańda, Yasuhiro Oki, Tatyana Feldman, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Jan Walewski, Robert Chen, Radhakrishnan Ramchandren, Pier Luigi Zinzani, David Cunningham, András Rosta, Neil C. Josephson, Eric Song, Jessica Sachs, Rachael Liu, Hina Jolin, Dirk Huebner, John Radford - New England Journal of Medicine 2017 被引用: 764

  5. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

    著者: Philippe Armand, Andreas Engert, Anas Younes, Michelle A. Fanale, Armando Santoro, Pier Luigi Zinzani, John M. Timmerman, Graham P. Collins, Radhakrishnan Ramchandren, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trněný, Margaret A. Shipp, Kazunobu Kato, Anne Sumbul, Benedetto Farsaci, Stephen M. Ansell - Journal of Clinical Oncology 2018 被引用: 754

  6. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

    著者: Matthew J. Reilley, Patricia McCoon, Carl Cook, Paul D. Lyne, Razelle Kurzrock, Youngsoo Kim, Richard Woessner, Anas Younes, John Nemunaitis, Nathan Fowler, Michael A. Curran, Qinying Liu, Tianyuan Zhou, Joanna Schmidt, Minji Jo, Samantha J. Lee, Mason Yamashita, Steven G. Hughes, Luis Fayad, Sarina A. Piha‐Paul, Murali V.P. Nadella, Xiaokun Xiao, Jeff Hsu, Alexey S. Revenko, Brett P. Monia, A. Robert MacLeod, David S. Hong - Journal for ImmunoTherapy of Cancer 2018 被引用: 288

  7. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

    著者: Anas Younes, Ajay K. Gopal, Scott E. Smith, Stephen M. Ansell, Joseph D. Rosenblatt, Kerry J. Savage, Radhakrishnan Ramchandren, Nancy L. Bartlett, Bruce D. Cheson, Sven de Vos, Andres Forero‐Torres, Craig H. Moskowitz, Joseph M. Connors, Andreas Engert, Emily K. Larsen, Dana A. Kennedy, Eric L. Sievers, Robert Chen - Journal of Clinical Oncology 2012 被引用: 1,520

  8. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma

    著者: Margaretha G.M. Roemer, Robert Redd, Fathima Zumla Cader, Christine J. Pak, Sara Abdelrahman, Jing Ouyang, Stephanie Sasse, Anas Younes, Michelle A. Fanale, Armando Santoro, Pier Luigi Zinzani, John M. Timmerman, Graham P. Collins, Radhakrishnan Ramchandren, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trněný, Stephen M. Ansell, Kazunobu Kato, Benedetto Farsaci, Anne Sumbul, Philippe Armand, Donna Neuberg, Geraldine S. Pinkus, Azra H. Ligon, Scott J. Rodig, Margaret A. Shipp - Journal of Clinical Oncology 2018 被引用: 367

  9. OncoTree: A Cancer Classification System for Precision Oncology

    著者: Ritika Kundra, Hongxin Zhang, Robert P. Sheridan, S. Joseph Sirintrapun, Avery Wang, Angelica Ochoa, Manda Wilson, Benjamin Groß, Yichao Sun, Ramyasree Madupuri, Baby A. Satravada, Dalicia N. Reales, Efsevia Vakiani, Hikmat Al‐Ahmadie, Ahmet Doǧan, Maria E. Arcila, Ahmet Zehir, Steven B. Maron, Michael F. Berger, Cristina Viaplana, Katherine A. Janeway, Matthew D. Ducar, Lynette M. Sholl, Snjezana Doğan, Philippe L. Bédard, Lea F. Surrey, Iker Huerga Sanchez, Aijaz Syed, Anoop Balakrishnan Rema, Debyani Chakravarty, Sarah P. Suehnholz, Moriah H. Nissan, Gopa Iyer, Rajmohan Murali, Nancy Bouvier, Robert A. Soslow, David M. Hyman, Anas Younes, Andrew M. Intlekofer, James J. Harding, Richard D. Carvajal, Paul Sabbatini, Ghassan K. Abou‐Alfa, Luc G.T. Morris, Yelena Y. Janjigian, Meighan M. Gallagher, Tara A. Soumerai, Ingo K. Mellinghoff, A. Ari Hakimi, Matthew G. Fury, Jason T. Huse, Aditya Bagrodia, Meera Hameed, Stacy B. Thomas, Stuart M. Gardos, Ethan Cerami, Tali Mazor, Priti Kumari, Pichai Raman, Priyanka Shivdasani, Suzanne P. MacFarland, Scott Newman, Angela J. Waanders, Jianjiong Gao, David B. Solit, Nikolaus Schultz - JCO Clinical Cancer Informatics 2021 被引用: 150

  10. Follicular lymphoma

    著者: Antonino Carbone, Sandrine Roulland, Annunziata Gloghini, Anas Younes, Gottfried von Keudell, Armando López‐Guillermo, Jude Fitzgibbon - Nature Reviews Disease Primers 2019 被引用: 261

  11. Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

    著者: Anas Younes, Nancy L. Bartlett, John P. Leonard, Dana A. Kennedy, Carmel M. Lynch, Eric L. Sievers, Andres Forero‐Torres - New England Journal of Medicine 2010 被引用: 1,353

  12. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting

    著者: Jie He, Omar Abdel‐Wahab, Michelle Nahas, Kai Wang, Raajit K. Rampal, Andrew M. Intlekofer, Jay Patel, Andrei V Krivstov, Garrett M. Frampton, Lauren Young, Shan Zhong, Mark Bailey, Jared White, Steven Roels, Jason Deffenbaugh, Alex Fichtenholtz, Timothy Brennan, Mark R. Rosenzweig, Kimberly Pelak, Kristina M. Knapp, Kristina Brennan, Amy Donahue, Geneva Young, Lázaro Ibrahim Romero García, Selmira T. Beckstrom, Mandy Zhao, Emily White, Vera Banning, Jamie Buell, Kiel Iwanik, Jeffrey S. Ross, Deborah Morosini, Anas Younes, Alan M. Hanash, Elisabeth Paietta, Kathryn G. Roberts, Charles G. Mullighan, Ahmet Doǧan, Scott A. Armstrong, Tariq I. Mughal, Jo-Anne Vergilio, Elaine LaBrecque, Rachel Erlich, Christine Vietz, Roman Yelensky, Philip J. Stephens, Vincent A. Miller, Marcel R.M. van den Brink, Geoff Otto, Doron Lipson, Ross L. Levine - Blood 2016 被引用: 309

  13. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

    著者: Anas Younes, Armando Santoro, Margaret A. Shipp, Pier Luigi Zinzani, John M. Timmerman, Stephen M. Ansell, Philippe Armand, Michelle A. Fanale, Voravit Ratanatharathorn, John Kuruvilla, Jonathon B. Cohen, Graham P. Collins, Kerry J. Savage, Marek Trněný, Kazunobu Kato, Benedetto Farsaci, Susan Parker, Scott J. Rodig, Margaretha G.M. Roemer, Azra H. Ligon, Andreas Engert - The Lancet Oncology 2016 被引用: 924

  14. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups

    著者: Connie Lee Batlevi, Fushen Sha, Anna Alperovich, Ai Ni, Katy Smith, Zhitao Ying, Jacob D. Soumerai, Philip Caron, Lorenzo Falchi, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Erel Joffe, Anita Kumar, Matthew J. Matasar, Alison J. Moskowitz, Craig H. Moskowitz, Ariela Noy, Colette Owens, Lia Palomba, David J. Straus, Gottfried von Keudell, Andrew D. Zelenetz, Venkatraman Seshan, Anas Younes - Blood Cancer Journal 2020 被引用: 203

  15. Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker

    著者: Megan M. Dacek, Keifer G. Kurtz, Patrick Wallisch, Stephanie Pierre, Shireen Khayat, Christopher M. Bourne, Thomas J. Gardner, Kristen Vogt, Nica Aquino, Anas Younes, David A. Scheinberg - Blood 2023 被引用: 46

  16. Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma

    著者: Patrizia Mondello, Saber Tadros, Matt Teater, Lorena Fontán, Aaron Y. Chang, Neeraj Jain, Haopeng Yang, Shailbala Singh, Hsia‐Yuan Ying, Chi-Shuen Chu, Man Chun John, Eneda Toska, Stefan Alig, Matthew Durant, Elisa de Stanchina, Sreejoyee Ghosh, Anja Mottok, Loretta J. Nastoupil, Sattva S. Neelapu, Oliver Weigert, Giorgio Inghirami, José Baselga, Anas Younes, Cassian Yee, Ahmet Doǧan, David A. Scheinberg, Robert G. Roeder, Ari Melnick, Michael R. Green - Cancer Discovery 2020 被引用: 159

  17. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies

    著者: David Sermer, Connie Lee Batlevi, M. Lia Palomba, Gunjan L. Shah, Richard J. Lin, Miguel‐Angel Perales, Michael Scordo, Parastoo B. Dahi, Martina Pennisi, Aishat Olaide Afuye, Mari Lynne Silverberg, Caleb Ho, Jessica Flynn, Sean M. Devlin, Philip Caron, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Erel Joffe, Anita Kumar, Matthew J. Matasar, Ariela Noy, Colette Owens, Alison J. Moskowitz, David J. Straus, Gottfried von Keudell, Ildefonso Rodriguez-Rivera, Lorenzo Falchi, Andrew D. Zelenetz, Joachim Yahalom, Anas Younes, Craig S. Sauter - Blood Advances 2020 被引用: 117

  18. Brentuximab Vedotin (SGN-35)

    著者: Jessica Katz, John E. Janik, Anas Younes - Clinical Cancer Research 2011 被引用: 363

  19. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

    著者: David J. Straus, Monika Długosz‐Danecka, Joseph M. Connors, Sergey Alekseev, Árpád Illés, Marco Picardi, Ewa Lech‐Marańda, Tatyana Feldman, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Jan Walewski, Radhakrishnan Ramchandren, Pier Luigi Zinzani, Martin Hutchings, Javier Muñoz, Hun Ju Lee, Won Seog Kim, Ranjana H. Advani, Stephen M. Ansell, Anas Younes, Andrea Gallamini, Rachael Liu, Meredith Little, Keenan Fenton, Michelle A. Fanale, John Radford - The Lancet Haematology 2021 被引用: 160

  20. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial

    著者: Anas Younes, Jesús G. Berdeja, Manish R. Patel, Ian W. Flinn, John F. Gerecitano, Sattva S. Neelapu, Kevin R. Kelly, Amanda Copeland, Amy Akins, Myles Clancy, Lucy Gong, Jing Wang, Anna Ma, Jaye L. Viner, Yasuhiro Oki - The Lancet Oncology 2016 被引用: 187

  21. Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review

    著者: Bertrand Coiffier, Arnold J. Altman, Ching‐Hon Pui, Anas Younes, Mitchell S. Cairo - Journal of Clinical Oncology 2008 被引用: 781

  22. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

    著者: Anas Younes, Patrick Hilden, Bertrand Coiffier, Anton Hagenbeek, Gilles Salles, Wyndham H. Wilson, John F. Seymour, Kara M. Kelly, John G. Gribben, M. Pfreunschuh, Franck Morschhauser, Heiko Schöder, Andrew D. Zelenetz, Jürgen Rademaker, Ranjana H. Advani, Nancy Valente, Catherine Fortpied, Thomas E. Witzig, Laurie H. Sehn, Andreas Engert, Richard I. Fisher, Pier Luigi Zinzani, Massimo Federico, Martin Hutchings, Catherine M. Bollard, Marek Trněný, Yusri Elsayed, Kensei Tobinai, Jeremy S. Abramson, Nathan Fowler, André Goy, Mitchell R. Smith, Stephen M. Ansell, John Kuruvilla, Martin Dreyling, Catherine Thiéblemont, Richard F. Little, Igor Aurer, Marinus H. J. van Oers, Kenichi Takeshita, Ajay K. Gopal, Simon Rule, Sven de Vos, Ioana Kloos, Mark Kaminski, Michel Meignan, Lawrence H. Schwartz, John P. Leonard, Stephen J. Schuster, Venkatraman Seshan - Annals of Oncology 2017 被引用: 377

  23. CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial

    著者: Yasuhiro Oki, Kevin R. Kelly, Ian W. Flinn, Manish R. Patel, Robert Gharavi, Anna Ma, Jefferson Parker, Amir Hafeez, David Tuck, Anas Younes - Haematologica 2017 被引用: 137

  24. Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials

    著者: Barbara C. M. Potts, M. Albitar, Kenneth C. Anderson, Stavroula Baritaki, Celia R. Berkers, Benjamin Bonavida, Joya Chandra, Dharminder Chauhan, James C. Cusack, William Fenical, Irene M. Ghobrial, M. Groll, Paul R. Jensen, Kentson Lam, G. Kenneth Lloyd, William H. McBride, David J. McConkey, Claudia P. Miller, Saskia Neuteboom, Yasuhiro Oki, Huib Ovaa, Frank Pajonk, PG Richardson, Aldo M. Roccaro, Callum M. Sloss, Matthew A. Spear, E. Valashi, Anas Younes, Michael A. Palladino - Current Cancer Drug Targets 2011 被引用: 239